Since upregulation of DDX41 is associated with poor survival, and hypoxia is associated with chemotherapy and radiotherapy resistance and poor therapeutic outcome (34), both hypoxia and DDX41 are considered disadvantageous to patients with HCC. This evidence concerns the gene DDX41 and hepatocellular carcinoma.